Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2208-2219

  Rahman, Mujib ^a,b   Miyamoto, Hiroshi ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ARA160 PROTEIN; ARA24 PROTEIN; ARA267 PROTEIN; ARA54 PROTEIN; ARA55 PROTEIN; ARA67 PROTEIN; ARA70 PROTEIN; BETA CATENIN; GELSOLIN; GLUCOCORTICOID; GONADORELIN DERIVATIVE; HYDROXYFLUTAMIDE; PROTEIN; RECEPTOR; SMAD3 PROTEIN; SMAD4 PROTEIN; SUPERVILLIN; TESTICULAR ORPHAN RECEPTOR 4; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; CANCER GROWTH; CASTRATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; DISEASE PROGRESSION; DNA; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 1842531175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0746-3     Document Type: Review

References (153)

1. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci 1996;1:d59-71.
2. McLachlan RI, Wreford NG, O'Donnell L, de Kretser DM, Robertson DM. The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. J Endocrinol 1996;148:1-9.
3. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1-28.
4. Tsai M-J, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
5. MacLean HE, Warne GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 1997;62:233-42.
6. Durand B, Saunders M, Gaudon C, et al. Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J 1994;13:5370-82.
7. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266:510-8.
8. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (Wash. DC) 1988;240:324-6.
9. Jemal A, Thomas A, Murray T, Thun, M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
10. Huggins C, Hodges CV. The effect of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
11. Greyhack J, Keeler T, Kozlowski J. Carcinoma of the prostate: hormonal therapy. Cancer (Phila.) 1987;60:589-601.
12. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy induces apoptosis in minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-75.
13. Prostate Cancer Trialist's Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
14. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
15. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (Bethesda) 2001;93:1687-97.
16. Visakorpi T. Molecular genetics of prostate cancer. Ann Chir Gynaecol 1999;88:11-6.
17. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
18. Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 1997;183:51-6.
19. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.
20. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
21. Palmberg C, Koivisto P, Hyytinen E, et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997;31:216-9.
22. Ishioka T, Tanatani A, Nagasawa K, Hashimoto Y. Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor. Bioorg Med Chem Lett 2003;13:2655-8.
23. Steketee K, Timmerman L, Ziel-van der Made AC, et al. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 2002;100:309-17.
24. Krishnan AV, Zhao XY, Swami S, et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 2002;143:1889-900.
25. Culig Z, Hobish A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
26. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000;42:239-42.
27. Craft N, Shostak Y, Carey M, Sawyears C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/neu tyrosine kinase. Nat Med 1999;5:280-5.
28. Yeh S, Lin, H-K, Kang H-Y, et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cells. Proc Natl Acad Sci USA 1998;96:5458-63.
29. Blok LJ, de Ruiter PE, Brinkmann AO. Androgen receptor phosphorylation. Endocr Res 1996;22:197-219.
30. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 1994;135:1359-66.
31. Nazarath LV, Weigle NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-7.
32. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
33. Bakin RE, Gioeli D, Sike RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9.
34. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-31.
35. Mckenna NJ, Xu J, Nawaz J, et al. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 1999;69:3-12.
36. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (Wash. DC) 1995;270:1354-7.
37. Voegel JJ, Heine M-J, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996;15:3667-75.
38. Le Douarin B, Zechel C, Gamier, J-M, et al. The N-terminal part of TIF-1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein. EMBO J 1995;14:2020-33.
39. Cavailles V, Dauvois S, L'Horset F, et al. Nuclear factor RIP 140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995;14:3741-51.
40. Puigserver P, Wu Z, Park CW, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-39.
41. Moilanen AM, Poukka H, Karvonen U, et al. Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol 1998;18:5128-39.
42. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
43. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (Lond.) 1997;389:194-8.
44. Debes JD, Schmidt LJ, Huang H, Tindall JD. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62:5632-6.
45. Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-60.
46. Fu M, Wang C, Wang J, et al. Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 2002;22:3373-88.
47. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002;277:25904-13.
48. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996;93:5517-21.
49. Kang H-Y, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 1999;274:8570-6.
50. Fujimoto N, Yeh S, Kang H-Y, et al. Isolation and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316-21.
51. Poukka H, Karvonen U, Yoshikawa N, et al. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 2000;113:2991-3001.
52. Alen P, Claessens F, Schoenmakers E, et al. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol Endocrinol 1999;13:117-28.
53. Gao T, Brantley K, Bolu E, McPhaul MJ. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol 1999;13:1645-56.
54. Heinlein CA, Ting H-J, Yeh S, Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ. J Biol Chem 1999;274:16147-52.
55. Hsu C-L, Yeh S, Chen Y-L, et al. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 2003;278:23691-8.
56. 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998;95:11083-8.
57. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379-84.
58. Miyamoto H, Chang C. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000;7:32-4.
59. Zhou ZX, He B, Hall SH, Wilson EM, French FS. Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol 2002;16:287-300.
60. Agoulnik I, Stenoien D, Mancini MA, Weigel N. Keystone Symposium, 2000, Nuclear Receptor Superfamily, Steamboat Springs, CO [abstract]. 302, 116.
61. Agoulnik IU, Krause WC, Bingman WE III, et al. Repressors of androgen and progesterone receptor action. J Biol Chem 2003;278:31136-48.
62. Han G, Foster BA, Mistry S, et al. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001;276:11204-13.
63. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-24.
64. Rahman MM, Miyamoto H, Takatera H, et al. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003;278:19619-26.
65. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
66. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-5.
67. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-50.
68. Shibanuma M, Mashimo J, Kuroki T, Nose K. Characterization of the TGF β1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 1994;269:26767-74.
69. Nishiya N, Sabe H, Nose K, Shibanuma M. The LIM domains of hic-5 protein recognize specific DNA fragments in a zinc-dependent manner in vitro. Nucleic Acids Res 1998;26:4267-73.
70. Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR. Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell 2000;11:2007-18.
71. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997;16:3145-57.
72. Bach I, Carriere C, Ostendorff HP, Andersen B, Rosenfeld MG. A family of LIM domain-associated cofactors confer transcriptional synergism between LIM and Otx homeodomain proteins. Genes Dev 1997;11:1370-80.
73. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001;58:289-94.
74. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003;100:5124-9.
75. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004;91:3-12.
76. Thomas SM, Hagel M, Turner CE. Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. J Cell Sci 1999;112:181-90.
77. Matsuya M, Sasaki H, Aoto H, et al. Cell adhesion kinase β forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem 1998;273:1003-14.
78. Wang X, Yang Y, Guo X, et al. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 2002;277:15426-31.
79. Stanzione R, Picascia A, Chieffi P, et al. Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Investig 2001;81:51-9.
80. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000;12:123-33.
81. Miyamoto H, Rahman M, Takatera H, et al. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002;277:4609-17.
82. Ito K, Adachi S, Iwakami R, et al. N-terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8. Eur J Biochem 2001;268:2725-32.
83. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
84. Hsiao P-W, Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 1999;274:22373-9.
85. Garcia JA, Ou SH, Wu F, et al. Cloning and chromosomal mapping of a human immunodeficiency virus 1 "TATA" element modulatory factor. Proc Natl Acad Sci USA 1992;89:9372-6.
86. Wang X, Yeh S, Wu G, et al. Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J Biol Chem 2001;276:40417-23.
87. Jenuwein T, Laible G, Dorn R, Reuter G. SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol Life Sci 1998;54:80-93.
88. Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9. Mol Cell Biol 2000;20:4900-9.
89. Gould A. Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev 1997;7:488-94.
90. Cardoso C, Timsit S, Villard L, et al. Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet 1998;7:679-84.
91. Cui X, De Vivo I, Slany R, et al. Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet 1998;19:331-7.
92. Huang N, vom Baur E, Garnier JM, et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 1998;17:3398-412.
93. Hsiao P-W, Lin D-L, Nakao R, Chang C. The linkage of Kennedy's disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 1999;274:20229-34.
94. Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999;15:607-60.
95. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002;161:1467-74.
96. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999;11:103-8.
97. Stossel TP, Chaponnier C, Ezzell RM, et al. Nonmuscle actin-binding proteins. Annu Rev Cell Biol 1985;1:353-402.
98. Fujita H, Allen PG, Janmey PA, et al. Induction of apoptosis by gelsolin truncates. Ann N Y Acad Sci 1999;886:217-20.
99. Koya RC, Fujita H, Shimizu S, et al. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 2000;275:15343-9.
100. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.) 2001;412:822-6.
101. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14-9.
102. Asch HL, Head K, Dong Y, et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996;56:4841-5.
103. Dosaka-Akita H, Hommura F, Fujita H, et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998;58:322-7.
104. Tanaka M, Mullauer L, Ogiso Y, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32.
105. Nishimura K, Ting H-J, Harada Y, et al. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 2003;63:4888-94.
106. Pope RK, Pestonjamasp KN, Smith KP, et al. Cloning, characterization, and chromosomal localization of human supervillin (SVIL). Genomics 1998;52:342-51.
107. Ting H-J, Yeh S, Nishimura K, Chang C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA 2002;99:661-6.
108. Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205): a novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J Cell Biol 1997;139:1255-69.
109. Truica CI, Byer S, Gelman EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-13.
110. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002;277:17933-43.
111. Pawlowski JE, Ertel JR, Allen MP, et al. Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002;277:20702-10.
112. Yan F, Li X, Sharma M, et al. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-44.
113. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21:2679-94.
114. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of β-catenin mutations in prostate cancer. Prostate 2000;45:323-34.
115. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-55.
116. Hao XP, Pretlow TG, Rao JS, Pretlow TP. β-Catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001;61:8085-8.
117. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J 2001;20:4912-22.
118. Voeller HJ, Truica CI, Gelmann EP. β-Catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-3.
119. Muscat GE, Burke LJ, Downes M. The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res 1998;26:2899-907.
120. Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373-80.
121. Heinzel T, Lavinsky RM, Mullen TM, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (Lond.) 1997;387:43-8.
122. Alland L, Muhle R, Hou H Jr, et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (Lond.) 1997;387:49-55.
123. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002;16:1492-501.
124. Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003;278:5052-61.
125. Reutens AT, Fu M, Wang C, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001;49:797-811.
126. Dedhar S, Rennie PS, Shago M, et al. Inhibition of nuclear hormone receptor activity by calreticulin. Nature (Lond.) 1994;367:480-3.
127. Sharma M, Zarnegar M, Li X, Lim B, Sun Z. Androgen receptor interacts with a novel MYST protein, HBOI. J Biol Chem 2000;275:35200-8.
128. Kang H-Y, Lin H-K, Hu Y-C, et al. From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001;98:3018-23.
129. Hayes SA, Zarnegar M, Sharma M, et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 2001;61:2112-8.
130. Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem 2002;277:1240-8.
131. Kang H-Y, Huang K-E, Chang S-Y, et al. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002;277:43749-56.
132. Massague J. Transforming growth factor-α. A model for membrane-anchored growth factors. J Biol Chem 1990;265:21393-6.
133. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.) 1994;371:257-61.
134. Attisano L, Wrana JL, Lopez-Casillas F, Massague J. TGF-β receptors and actions. Biochim Biophys Acta 1994;122:71-80.
135. Lamm ML, Sintich SM, Lee C. A proliferative effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology 1998;139:787-90.
136. Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-β1 in prostate cancer. Microsc Res Tech 2001;52:411-9.
137. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-61.
138. Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998;4:1625-30.
139. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-71.
140. Guo Y, Kyprianou N. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 1998;9:185-93.
141. Barrack ER. TGF β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
142. Cui W, Fowlis DJ, Bryson S, et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
143. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond.) 1985;316:701-5.
144. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1995;1:282-4.
145. Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7.
146. Chang C, Da Silva SL, Ideta R, et al. Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily. Proc Natl Acad Sci USA 1994;91:6040-4.
147. Lee Y-F, Young W-J, Burbach JP, Chang C. Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily. J Biol Chem 1998;273:13437-43.
148. Lee Y-F, Pan H-J, Burbach JP, Morkin E, Chang C. Identification of direct repeat 4 as a positive regulatory element for the human TR4 orphan receptor. A modulator for the thyroid hormone target genes. J Biol Chem 1997;272:12215-20.
149. 3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. J Biol Chem 1999;274:16198-205.
150. Young W-J, Smith SM, Chang C. Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFRα) gene by the TR4 orphan receptor. A member of steroid receptor superfamily. J Biol Chem 1997;272:3109-16.
151. Lee Y-F, Shyr C-R, Thin TH, Lin W-J, Chang C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc Natl Acad Sci USA 1999;96:14724-9.
152. Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 2004;24:1044-57.
153. Zheng P, Eastman J, Vande Pol S, Pimplikar SW. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc Natl Acad Sci USA 1998;95:14745-50.